• Minicabecera4

The biopharmaceutical company Histocell boosts its internationalisation with international investors and new distribution agreements

 MG 2959 web

The Basque biopharmaceutical company Histocell, belonging to the NorayBio Group, reinforces its internationalization strategy with the recent inauguration of its production plant in the Basque Country.

The entry of a new Japanese investment fund and the achievement of 6 new distribution agreements for REOXCARE internationally, are part of the firm commitment of the company to internationalisation, which allows marketing its products in the largest number of markets.

Capital increase with a Japanese investment fund

The company has also significantly increased its capital as the result of the entry of the Japanese investment fund Cell Innovation Partners that specializes in regenerative medicine and cell therapy and whose main partners are the Japanese company Reprocell and bank Shinsei. This is the first investment of this fund in a biopharmaceutical company in Spain. In this financing round, the main current partners of Histocell have also participated.

Reoxcare to be marketed in 20 countries

Reoxcare, a product already present in the Spanish market, opened its doors to the international market in 2017 with the first agreements in Europe, Asia, the Middle East and Latin America. Histocell's short-term expansion plan includes several countries, such as China, Hong Kong, Jordan, Saudi Arabia, Colombia, Peru, Chile, Ecuador, Panama, and Mexico, as well as the Netherlands, Austria, Italy, and Portugal.

New production plant for a greater process control

The new production facility for medical devices, which required an investment of 1.6 million euros demonstrates the company's commitment to maintaining both its research and manufacturing activities in Spain.

The new plant initially has two production lines. One line for the treatment of hard to heal wounds, Reoxcare, for humans and Vexoderm for veterinary medicine, and another, with products like Wharton Gel Complex and Histoessence. Rexocare is an innovative wound dressing, unique in the international market, which is produced with materials from natural origin. It has clearly demonstrated its differential value in the healing of complex wounds where other conventional treatments have failed. Histocell foresees an annual production of 100,000 units of the dressings, 400 kilograms of the cosmetic ingredient Wharton Gel Complex, and up to 200,000 vials of Histoessence. In total, the company estimates that the products manufactured in the new facilities will reach sales of 6 million euros in 2021.

The new manufacturing plant joins the GMP clean room accredited by the Spanish Agency of Medicines and Medical Devices, which is located on the premises of the firm at the Science and Technology Park of Bizkaia in Derio, where Histocell will continue manufacturing its stem cell-based therapy drugs. These drugs are currently in clinical phase trials in several Spanish hospitals. Results from the first patients treated with these cell-based drugs are very promising.

About Histocell

Histocell is a biopharmaceutical company focused on the development of medicines and health products for regenerative medicine and cell therapy. It has 25 highly specialized employees and production facilities authorized by the Spanish Agency of Medicines and Medical Devices for the manufacture of cell therapy drugs.

    Its main programs include:
  • Development of cell therapy drugs based on the proprietary cellular platform HC016 for the treatment of diseases mediated by oxidative stress (acute spinal cord injury, acute lung disease or critical ischemia of the lower extremities), and Bonecure for bone regeneration. Both drugs are currently in Phase I / II clinical trials in patients.
  • Development of medical devices protected by patents, for the treatment of various diseases such as chronic ulcers, bone and cartilage defects, oral mucosal lesions...
  • Components and medical devices for facial and hair cosmetics.
  • GMP production of cell therapy products for third parties.